摘要
Immune therapy is a new avenue in the treatment of multiple myeloma(MM).The naked anti-38 antibodies daratumumab and isatuximab are already used in frontline therapy after excellent results have been achieved in relapsed/refractory MM(RRMM).The second step was the development of immune therapies targeting B cell maturation antigen(BCMA).Genetically modified autologous chimeric antigen receptor(CAR)-T cell therapy BCMA-directed were initially tested in heavily pretreated patients with RRMM exposed to the 3 main therapeutic classes,immunomodulatory drugs(iMiDs),proteasome inhibitors,and anti-CD38 antibodies(triple-class exposed).Efficacy results were unprecedented in this context and Idecabtagene vicleucel(ide-cel or Abecma)was the first BCMA-directed CAR-T cell therapy approved in MM by both Federal Drug Administration(FDA)and European Medicines Agency(EMA).
